BECTON DICKINSON MEDICAL SYSTEMS 10 ML BD¿ PRE-FILLED NORMAL SALINE SYRINGE, IN 10 ML SYRINGE; PREFILLED SALINE FLUSH SYRINGE
|
Back to Search Results |
|
Catalog Number 306500 |
Device Problems
Nonstandard Device (1420); Microbial Contamination of Device (2303)
|
Patient Problems
Pain (1994); Swelling (2091); Burning Sensation (2146); Ambulation Difficulties (2544); Dysuria (2684)
|
Event Date 05/10/2018 |
Event Type
Injury
|
Manufacturer Narrative
|
Date of event: unknown.The date received by manufacturer has been used for this field.A device evaluation is anticipated, but has not yet begun.Upon completion of the investigation, a supplemental report will be filed.
|
|
Event Description
|
It was reported that a patient experienced swelling, painful leg muscles, difficulty walking, sitting, and standing, and had pain and burning during urination.The patient was treated with lyrica and received x-rays which were unremarkable.The patient associated these symptoms with the use of a 10 ml bd¿ pre-filled normal saline syringe, in 10 ml syringe.*out of an abundance of caution and in the interest of public health, bd voluntarily recalled certain lots of bd posiflush¿ heparin lock flush and bd¿ pre-filled normal saline flush syringes due to a potential for contamination with serratia marcescens bacterium.Bd was notified by the u.S.Food and drug administration (fda) and centers for disease control and prevention (cdc) about a potential epidemiological link between catheter related blood stream infections and the s.Marcescens bacterium.Specifically, the fda and cdc identified a potential connection between reports of infection in a small number of patients caused by s.Marcescens across multiple states.Cdc¿s initial investigation found that affected patients had received treatment using certain bd flush products.To date, there is no evidence of bd flush product testing positive for this bacterium.Investigations are ongoing by bd, fda, and cdc.
|
|
Manufacturer Narrative
|
Investigation summary: lot number: 728611d for product code: 306500 was provided for evaluation by our quality engineer team.Upon reviewing the production history for the provided lot number, no deviations or non-conformances were identified during the manufacturing process.A corrective and preventive action plan was initiated to further investigate and monitor this issue.One-hundred and twenty retained samples for the lot number provided were visually inspected and no abnormalities were observed in regards to the solution.A review of all lot sterility testing performed for product released between april 2015 and june 2018 confirmed that no organism growth was identified for any lots released during the shelf-life of this product.Multiple samples produced before and after the provided lot number were sent for sterility testing and confirmed that no microbial growth was exhibited after incubation.This in combination with the daily environmental monitoring and sterility testing provides confidence in the sterility of the reported lot number.A direct causation between the reported infections and reactions and the bd franklin product has not been identified.Investigation conclusion: the root cause analysis of the reported infection/reaction cases under capa 350041 has not identified a directed causation between the infections/reactions and the bd franklin product.
|
|
Event Description
|
It was reported that a patient experienced swelling, painful leg muscles, difficulty walking, sitting, and standing, and had pain and burning during urination.The patient was treated with lyrica and received x-rays which were unremarkable.The patient associated these symptoms with the use of a 10 ml bd¿ pre-filled normal saline syringe, in 10 ml syringe.Out of an abundance of caution and in the interest of public health, bd voluntarily recalled certain lots of bd posiflush¿ heparin lock flush and bd¿ pre-filled normal saline flush syringes due to a potential for contamination with serratia marcescens bacterium.Bd was notified by the u.S.Food and drug administration (fda) and centers for disease control and prevention (cdc) about a potential epidemiological link between catheter related blood stream infections and the s.Marcescens bacterium.Specifically, the fda and cdc identified a potential connection between reports of infection in a small number of patients caused by s.Marcescens across multiple states.Cdc¿s initial investigation found that affected patients had received treatment using certain bd flush products.To date, there is no evidence of bd flush product testing positive for this bacterium.Investigations are ongoing by bd, fda, and cdc.
|
|
Search Alerts/Recalls
|
|
|